Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

Who May Qualify: - Patients over 18 years of age; - Histological diagnosis of clear cell renal cell carcinoma; - Evidence of advanced or metastatic disease; - Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI); - Patients able to comply with the study procedures. - Patients who give written willing to sign a consent form personally or through a witness (study participation and data processing), before any study-specific procedure is started. Who Should NOT Join This Trial: - Previous neoplasms; - Previous antineoplastic treatments; - Previous steroid treatments; - Active viral infections (e.g., HCV, HIV, etc.); - Lack of autonomy in adhering to study procedures. Always talk to your doctor about whether this trial is right for you.